Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–12 of 12 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Centrexion Therapeutics Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects

NCT03787004
View directory record Official record
Conditions
Chronic Pain, Nociceptive Pain
Interventions
CNTX-6970, Placebo
Drug · Other
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)

NCT00667654
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
CNTX-4975
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain

NCT03660943
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Placebo, CNTX-4975-05
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
30
States / cities
Glendale, Arizona • Phoenix, Arizona • Carmichael, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability & Pharmacokinetics Study of CNTX-6016 in Healthy Subjects and Subjects With PDN

NCT04857957
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
Oral dose CNTX-6016 or oral dose Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years to 59 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain

NCT02558439
View directory record Official record
Conditions
Osteoarthritis
Interventions
CNTX-4975, Placebo
Drug · Other
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
45 Years to 80 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

NCT02678793
View directory record Official record
Conditions
Morton's Neuroma
Interventions
CNTX-4975
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • El Cajon, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 3, 2026, 6:08 PM EDT
Recruiting Phase 1 Interventional

Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain

NCT07122453
View directory record Official record
Conditions
Lower Back Pain
Interventions
CNTX-3001, Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Napa, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

An Open-label, 8-week Safety, Efficacy, and Assessment of Cooling Methods for Administration of CNTX-4975-05 for Knee OA

NCT03661996
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Lidocaine without epinephrine, ElastoGel, Breg Ice Water Pump
Drug · Device
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
854 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)

NCT02283957
View directory record Official record
Conditions
Painful Intermetatarsal Neuroma (Morton's Neuroma)
Interventions
CNTX-4975, Placebo
Drug · Other
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Castro Valley, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 1 Interventional

A Study to Compare Levels of Capsaicin After Intra-Articular Injection and Topical Application in Patients With Painful Knee Osteoarthritis

NCT03576508
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
CNTX-4975-05, Qutenza, Lidocaine (without epinephrine)
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
50 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Efficacy and Safety Study of Intra-articular CNTX-4975-05 (Capsaicin) vs Placebo in Subjects With OA Knee Pain

NCT03429049
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
CNTX-4975-05, Placebo
Drug
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
40 Years to 95 Years
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 3, 2026, 6:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

NCT04154501
View directory record Official record
Conditions
Chronic Pain, Nociceptive Pain, Pain
Interventions
CNTX-6016, Other: Placebo
Drug · Other
Lead sponsor
Centrexion Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 3, 2026, 6:08 PM EDT